Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET

Company Participants

David Szekeres - EVP and COO

Barry Quart - CEO and Chairman

John Poyhonen - President and Chief Commercial Officer

Conference Call Participants

Brandon Folkes - Cantor Fitzgerald

Josh Schimmer - Evercore

Serge Belanger - Needham and Company

Operator

Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics Q3 2022 Earnings Conference. As a reminder, this conference is being recorded.

Now I would like to turn the call over to David Szekeres, Executive Vice President, Chief Operating Officer. Please proceed.

David Szekeres

Thank you, Dennis. Good afternoon, everyone, and thank you for joining us. With me today from Heron are Barry Quart, Chief Executive Officer and Chairman; John Poyhonen, President and Chief Commercial Officer; and Kimberly Manhard, Executive Vice President of Drug Development and Board Director.

For those of you participating via conference call, the slides are made available via webcast and can also be accessed by going to the Investor Relations page of our website, following conclusion of today's call.

Before we begin, I would like to remind you that this call will contain forward-looking statements concerning Heron's future expectations, plans, prospects, corporate strategy and performance, which constitute forward-looking statements for the purposes of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements, as a result of various important factors, including those discussed in our filings with the SEC.

In addition, any forward-looking statements represent our views only as of the date of this webcast and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update such statements.

Now, I’ll turn the call over to Barry.

Barry Quart

Thank you, David. Welcome everyone. And thank you for joining us.

Third quarter has been productive on a number of fronts and disappointing on others. We're obviously delighted with the approval of APONVIE, our fourth commercial product. APONVIE is indicated for the prevention of postoperative nausea and vomiting or PONV in adults. APONVIE will be available in first quarter as a very convenient room temperature stable, ready-to-use 32 milligram single dose vial for direct administration as a 30 second intravenous injection. prior to induction of anesthesia. It will be the only intravenous NK1 receptor antagonist available for PONV.